Staphylococcus epidermidis vaccine conjugate (Nabi)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameStaphylococcus epidermidis vaccine conjugate (Nabi)

Drug Alias NameStaphylococcus epidermidis (PS-1) vaccine conjugate

ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsStaphylococcal Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNabi Biopharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNabi Biopharmaceuticals

Active IndicationsN/A

Inactive IndicationsStaphylococcal Infections

Other Information

ATC CodeN/A